NEW YORK, NY--(Marketwire - May 4, 2012) - [ www.shinesrooms.com ] has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Spectrum Pharmaceuticals Inc. (NASDAQ: [ SPPI ]) and Amgen Inc. (NASDAQ: [ AMGN ]). Register with us today at [ http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index ] to have free access to these research reports.

There have been some positive first quarter results coming out of the healthcare biotechnology industry. Spectrum Pharmaceuticals Inc. recently reported first quarter earnings per share of $0.71, well above year ago earnings of $0.23 per share. Revenues also increased above year ago levels of $44 million, reaching $60 million. Get your free reports on Spectrum Pharmaceuticals Inc. and Amgen Inc. at [ http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index ]. There is no commitment to join.

[ www.shinesrooms.com ] is the Ultimate Trading Environment for investors. If you are considering owning Spectrum Pharmaceuticals Inc. and Amgen Inc. then you should sign up for a free membership and our complimentary reports today at [ www.shinesrooms.com ]. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Spectrum has also newly announced its decision to bump up its U.S. manufacturing capacity of Fusilev which was recently approved as a treatment for colorectal cancer. Spectrum Pharmaceuticals Inc. report is accessible for free by registering today at [ http://www.shinesrooms.com/SpectrumPharmaceuticalsInc040512.pdf ].

Year-over-year improvements could also be seen in the first quarter report of Amgen Inc. Earnings per share at Amgen were $1.59 per share, 20.5 percent higher than a year ago. Total revenues increased by 9.2 and a lower tax rate and share count were also positives. Amgen has been working hard to expand its international reach and market share, with plans to have operations in 75 countries by 2015. Most recently it has agreed to acquire 95.6 percent of shares of Turkish company Mustafa Nevzat Pharmaceuticals. Amgen Inc. report is accessible for free by registering today at [ http://www.shinesrooms.com/AmgenInc040512.pdf ].

The two Biotechnology stocks research reports are available for free by signing up now on [ www.shinesrooms.com ].

About Shinesrooms.com

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link [ http://www.shinesrooms.com/disclaimer.html ].